modelCalciumGluconate
Extends from Pharmacolibrary.Drugs.ATC.D.D11AX03.
Information
| name: | CalciumGluconate | |
| ATC code: | D11AX03 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 0.24 | L/h/kg |
| other parameters in model implementation | ||
Calcium gluconate is an intravenous or oral calcium salt used in the treatment and prevention of hypocalcemia, as well as in conditions like tetany, hypoparathyroidism, and for hyperkalemia or hypermagnesemia emergencies. It is also used topically (ATC D11AX03) for treating skin burns from hydrofluoric acid. It is approved and currently used for these indications.
Pharmacokinetics
No specific pharmacokinetic models reporting volume of distribution, clearance, or related PK model parameters for topical or systemic (IV, oral) calcium gluconate were found in indexed scientific literature for healthy adults or patient populations; estimates provided are based on calcium PK properties and clinical use.
References
Ansari, JR, et al., & Shafer, SL (2025). Bioequivalence and Pharmacokinetics of Intravenous Calcium during Cesarean Delivery. Anesthesiology 142(1) 121–131. DOI:10.1097/ALN.0000000000005248 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39361822
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Kaisbain, N, et al., & Kaisbain, V (2023). Verapamil-Induced Hypotension in End-Stage Renal Disease: The Role of Calcium Gluconate. Cureus 15(1) e33341–None. DOI:10.7759/cureus.33341 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36741660
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)